Jana Winckler

417 total citations
21 papers, 225 citations indexed

About

Jana Winckler is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Jana Winckler has authored 21 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 10 papers in Pediatrics, Perinatology and Child Health and 9 papers in Epidemiology. Recurrent topics in Jana Winckler's work include Tuberculosis Research and Epidemiology (14 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (7 papers). Jana Winckler is often cited by papers focused on Tuberculosis Research and Epidemiology (14 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (7 papers). Jana Winckler collaborates with scholars based in South Africa, United States and Germany. Jana Winckler's co-authors include Anneke C. Hesseling, H. Simon Schaaf, Anthony J. Garcia‐Prats, Lubbe Wiesner, Heather R. Draper, Rada Savic, Paolo Denti, Helen McIlleron, Stephanie Thee and Maria Garcia‐Cremades and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and PLoS Medicine.

In The Last Decade

Jana Winckler

20 papers receiving 224 citations

Peers

Countries citing papers authored by Jana Winckler

Since Specialization

Citations

This map shows the geographic impact of Jana Winckler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Winckler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Winckler more than expected).

Fields of papers citing papers by Jana Winckler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Winckler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Winckler. The network helps show where Jana Winckler may publish in the future.

Co-authorship network of co-authors of Jana Winckler

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Winckler. A scholar is included among the top collaborators of Jana Winckler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Winckler. Jana Winckler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Children and providers’ perspectives on once-weekly rifapentine and isoniazid TB preventive therapy 2025 ·PubMed ·(unknown), Dillon T. Wademan, (unknown), Yael Hirsch‐Moverman, Lario Viljoen, Jana Winckler, (unknown), (unknown), Shaun Barnabas, (unknown), Anneke C. Hesseling, Graeme Hoddinott	1
2	Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), Anthony J. Garcia‐Prats, Helen McIlleron, (unknown), Jana Winckler, Heather R. Draper, Lubbe Wiesner, H. Simon Schaaf, Anneke C. Hesseling, Paolo Denti	2
3	Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), Anneke C. Hesseling, Jana Winckler, H. Simon Schaaf, Heather R. Draper, (unknown), Jennifer Hughes, (unknown), James C. Nielsen, Lubbe Wiesner, Anthony J. Garcia‐Prats, Radojka M. Savić	3
4	QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), Anneke C. Hesseling, Jana Winckler, H. Simon Schaaf, Heather R. Draper, (unknown), (unknown), Jennifer Hughes, (unknown), James C. Nielsen, Anthony J. Garcia‐Prats, Rada Savic	4
5	Children´s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa 2023 ·The International Journal of Tuberculosis and Lung Disease ·Dillon T. Wademan, Lario Viljoen, (unknown), (unknown), (unknown), (unknown), H. Simon Schaaf, Anneke C. Hesseling, Jana Winckler, Anthony J. Garcia‐Prats, Graeme Hoddinott	2
6	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis 2022 ·Antimicrobial Agents and Chemotherapy ·(unknown), Anthony J. Garcia‐Prats, H. Simon Schaaf, Maxwell Chirehwa, Jana Winckler, Jun J. Mao, Heather R. Draper, Lubbe Wiesner, Jennifer Norman, Helen McIlleron, Peter R. Donald, Anneke C. Hesseling, Paolo Denti	1
7	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis 2022 ·Clinical Infectious Diseases ·Jennifer Hughes, (unknown), Heather R. Draper, H. Simon Schaaf, Jana Winckler, (unknown), (unknown), (unknown), Lubbe Wiesner, Anneke C. Hesseling, Radojka M. Savić, Anthony J. Garcia‐Prats	7
8	Treatment outcomes and safety in children with rifampicin-resistant TB 2022 ·The International Journal of Tuberculosis and Lung Disease ·Elisa López‐Varela, Anthony J. Garcia‐Prats, James A. Seddon, Heather R. Draper, Jana Winckler, (unknown), Megan Palmer, (unknown), H. Simon Schaaf, Anneke C. Hesseling	6
9	Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and Outcome 2022 ·The Pediatric Infectious Disease Journal ·(unknown), Heather R. Draper, Anthony J. Garcia‐Prats, Jana Winckler, Anneke C. Hesseling, H. Simon Schaaf	0
10	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study 2021 ·Clinical Infectious Diseases ·Paolo Denti, Roeland E. Wasmann, Annelies Van Rie, Jana Winckler, Adrie Bekker, Helena Rabie, Anneke C. Hesseling, (unknown), Carmen González-Martínez, Heather J. Zar, Geraint Davies, Lubbe Wiesner, Elin M. Svensson, Helen McIlleron	18
11	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis 2021 ·Frontiers in Pharmacology ·(unknown), Anthony J. Garcia‐Prats, H. Simon Schaaf, Jana Winckler, Heather Draper, Jennifer Norman, Lubbe Wiesner, Helen McIlleron, Paolo Denti, Anneke C. Hesseling	4
12	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial 2021 ·Journal of Antimicrobial Chemotherapy ·Anthony J. Garcia‐Prats, Elin M. Svensson, Jana Winckler, Heather R. Draper, Lee Fairlie, (unknown), Masebole Masenya, H. Simon Schaaf, Lubbe Wiesner, Jennifer Norman, Rob E. Aarnoutse, Mats O. Karlsson, Paolo Denti, Anneke C. Hesseling	22
13	Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children 2021 ·Clinical Infectious Diseases ·(unknown), Anneke C. Hesseling, Jana Winckler, Heather R. Draper, (unknown), Stephanie Thee, Lubbe Wiesner, (unknown), (unknown), James C. Nielsen, H. Simon Schaaf, Radojka M. Savić, Anthony J. Garcia‐Prats	19
14	Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis 2020 ·Journal of the Pediatric Infectious Diseases Society ·Paul Krogstad, Pearl Samson, Edward P. Acosta, Jack Moye, Ellen Townley, Sarah Bradford, (unknown), (unknown), Bobbie Graham, (unknown), (unknown), Hedy Teppler, (unknown), Lee Fairlie, Jana Winckler, (unknown), Tammy Meyers	7
15	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies 2019 ·PLoS Medicine ·Anthony J. Garcia‐Prats, H. Simon Schaaf, Heather R. Draper, Maria Garcia‐Cremades, Jana Winckler, Lubbe Wiesner, Anneke C. Hesseling, Rada Savic	44
16	Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin 2019 ·Journal of Antimicrobial Chemotherapy ·Helena Rabie, Holly Rawizza, Peter Zuidewind, Jana Winckler, Heather J. Zar, Annelies Van Rie, Lubbe Wiesner, Helen McIlleron	4
17	Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis 2018 ·Clinical Infectious Diseases ·Anthony J. Garcia‐Prats, Heather R. Draper, Heather Finlayson, Jana Winckler, (unknown), (unknown), Stephanie Thee, Anneke C. Hesseling, H. Simon Schaaf	19
18	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis 2017 ·Antimicrobial Agents and Chemotherapy ·Paolo Denti, Anthony J. Garcia‐Prats, Heather R. Draper, Lubbe Wiesner, Jana Winckler, Stephanie Thee, Kelly E. Dooley, Rada Savic, Helen McIlleron, H. Simon Schaaf, Anneke C. Hesseling	38
19	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis 2017 ·Antimicrobial Agents and Chemotherapy ·(unknown), Anthony J. Garcia‐Prats, H. Simon Schaaf, (unknown), Lubbe Wiesner, (unknown), Jana Winckler, Jennifer Norman, Helen McIlleron, Paolo Denti, Anneke C. Hesseling	10
20	Long-term “in vitro” proliferating mouse hematopoietic progenitor cell lines 2010 ·Immunology Letters ·(unknown), Jana Winckler, Fritz Melchers	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact